- Home
- BUDA vs BDTX Comparison
BUDA vs BDTX Comparison
Compare BUDA & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BUDA | BDTX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.7M | 104.0M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BUDA | BDTX |
|---|---|---|
| Price | $6.75 | $1.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $13.00 | $10.00 |
| AVG Volume (30 Days) | 2.8K | ★ 857.8K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $12,609,000.00 | N/A |
| Revenue This Year | $35.68 | N/A |
| Revenue Next Year | $21.58 | N/A |
| P/E Ratio | $96.79 | ★ N/A |
| Revenue Growth | ★ 11.84 | N/A |
| 52 Week Low | $6.25 | $1.60 |
| 52 Week High | $12.00 | $4.94 |
Technical Indicators
Market Signals| Indicator | BUDA | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.22 | 44.60 |
| Support Level | $7.42 | $1.61 |
| Resistance Level | $8.01 | $1.93 |
| Average True Range (ATR) | 0.44 | 0.15 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 69.60 | 29.63 |
Price Performance
Historical ComparisonAbout BUDA Buda Juice Inc. Common Stock
Buda Juice Inc operates in a beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never heat-treated, pasteurized, never HPP- processed, never UV- treated and always cold.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.